Enclosed are your last three posts which forgive me I have cut and pasted into one. Collectively they make for very good reading and may I say have the appearance of an un-official r n s. You have a very good grasp of the subject matter which to me would suggest a pharmaceutical / medical background. Please continue with the highly welcome information posted thus far. ;+)
The thing is I think we are in a bit of a sweet spot at the moment. The pace of genetic decoding (which patient base are most likely to respond).- see ICR increasing newsflow. The specificity with which individual & combination kinsases are linked to specific diseases. We could have gone into a Chk1 P1 trial a year go and got so so results. We can now pick a disease subtype, pick the population subset we know it will hit and get super results. (i.e. on Chk1 do we go for Colon, paediatric neuroblastoma, or head and neck solid tumors. Do we go sole agent or combination). or a mixture. Reducing risk, reducing costs, increasing likelihood of an orphan designation to fast track approval and then piggy back other indications.
The same principle applies to our other in house candidates, but the knowledge we gain from Chk1 approach is applicable.
Sareum don't want to be the first to market. They want to be the best. There is a "second mover" advantage to be had with the pace of related discoveries (incl biomarkers) at the moment. TYK2 is particularly hot if you look at research funding & papaers last 2 years.
I honestly believe we have found ourselves in the right place at the right time, and the BOD recognises this. a little patience.
no. a lot of patience needed. takes years to move into the clinic, and deals can be done at any time over that period, (or not). But in the meantime the co improves the quality of supporting data and the molecules (steadily increasing value) for when a deal is done. I personally think ICR may take Chk1 into phase 1 itself (via the DDO mechanism). However they have recently moved into P1 on a collaboration with Astellas that started TEN years ago in preclinical. If we do think we have the best molecules and the most comprehensive patents, no point doing a deal unless the value fully reflects that. so Im unconcerned on timings and fluctuations in sp in the meantime. Part of the beauty of this is the low cash burn, and lack of spin. This is because they don't have a big management team, I wouldnt want that model to change.
we don't need wider managerial skills. they've done deals before. CRT are the second largest dealmaker in oncology over the last 10 years. you just need more patience if you are investing in biotech.
Elgouna why do you think it is a very low SP? loss making comapny, a few possible compounds that would need a lot of luck and massive funding to make commercial and a BOD of promise promise promise and then say f all for month after month
Moons. Completely concur and the knowledge from him / her is like a shining beacon out of the gloom right now.
Paisley. Thanks for your post and on reflection maybe you are right that I'm taking TM's lack of response personally best I grow up and move on and take the emotion out of any of my thought processes. ;+)
Andy- I suspect you are taking the delay a bit personally. After all....you attended the AGM and received certain information face to face- they looked you in the eye and made certain assurances; and then in good faith you passed them onto our community... I think I can understand why you in particular would feel aggrieved about a lack of supporting information in the nearly four months since.
I have sold down my stake in SAR, partly as a result of poor communications and the concern it gives rise to; partly in response to the downward trend. I am still here though largely for reasons of a bit of diversity in the biotech sector.
Mrsape- your contribution looks very credible. If correct, however, then what a shame SAR aren't able to communicate such thoughts.
I tend to agree that an NED could help the company in it's shareholder relations. It seems to me Tim needs to step back and concentrate on the science. An NED - or someone(!) with a brief on shareholder relations could benefit us all- Tim included. It can't be pleasant seeing the kind of stuff that gets posted on here.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.